14 results
10-K
2023 FY
NMRA
Neumora Therapeutics, Inc. Common Stock
7 Mar 24
Annual report
4:05pm
-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made … clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public
424B4
NMRA
Neumora Therapeutics, Inc. Common Stock
18 Sep 23
Prospectus supplement with pricing info
4:12pm
-kickback, fraud and abuse, false claims, physician payment transparency, and other healthcare laws and regulations, which could expose us to substantial … . In addition, we may be subject to physician payment transparency laws and regulation by the federal government and by the states and foreign jurisdictions
S-1/A
NMRA
Neumora Therapeutics, Inc. Common Stock
11 Sep 23
IPO registration (amended)
6:07am
to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, and other healthcare laws and regulations, which could expose us … marketing approval. In addition, we may be subject to physician payment transparency laws and regulation by the federal government and by the states
S-1
lykxb9hp9kdo77o1
25 Aug 23
IPO registration
5:03pm
DRS/A
cs51g6hyj2e01
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
kz0jz7 pyz00900n
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
lyp0jkrrfujxfb
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
7kk27is qv3ju3
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
a7tlpb
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
c5d smgma98yx9uclur
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
7gpoiut
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
7ke59ukb3 x4z157a
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next